AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Protein phosphatase methylesterase 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9Y570

UPID:

PPME1_HUMAN

Alternative names:

-

Alternative UPACC:

Q9Y570; B3KMU6; B5MEE7; J3QT22; Q8WYG8; Q9NVT5; Q9UI18

Background:

Protein phosphatase methylesterase 1 (PPME1) plays a crucial role in cellular processes by demethylating proteins that have undergone reversible carboxymethylation. It specifically targets and demethylates PPP2CB and PPP2CA, key components in the protein phosphatase 2 (PP2A) complex, which is essential for cell cycle regulation, signal transduction, and other critical cellular activities. By binding to PPP2CA, PPME1 displaces the manganese ion, rendering the enzyme inactive.

Therapeutic significance:

Understanding the role of Protein phosphatase methylesterase 1 could open doors to potential therapeutic strategies. Its involvement in the regulation of PP2A, a complex pivotal to numerous cellular functions, highlights its potential as a target in diseases where PP2A activity is dysregulated.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.